Coda Octopus Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Coda Octopus Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | $20.32M | Jan 29, 2025 |
| FY2024 | Oct 31, 2023 | $19.35M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $22.23M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $21.33M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $20.04M | Feb 14, 2022 |
| FY2018 | Oct 31, 2018 | $18.02M | Feb 7, 2019 |
| FY2018 | Oct 31, 2017 | $18.03M | Feb 7, 2019 |
| FY2017 | Oct 31, 2016 | $21.12M | Jan 30, 2018 |
| FY2010 | Oct 31, 2010 | $11.51M | Aug 19, 2016 |
| FY2010 | Oct 31, 2009 | $13.22M | Aug 19, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $26.56M | Feb 26, 2026 |
| FY2025 | Oct 31, 2025 | 26.56M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 20.32M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $20.32M | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | $19.35M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $22.23M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $21.33M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $20.04M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $25.06M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $18.02M | Jan 28, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $17.66M | Feb 26, 2026 |
| FY2025 | Oct 31, 2025 | 17.66M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 14.17M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $14.17M | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | $13.03M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $15.19M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $14.77M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $12.73M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $16.43M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $12.66M | Jan 28, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $4.13M | Feb 26, 2026 |
| FY2025 | Oct 31, 2025 | 4.13M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 3.65M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $3.65M | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | $3.12M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $4.30M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $4.95M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $3.34M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $5.23M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $4.99M | Jan 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $4.54M | Feb 26, 2026 |
| FY2025 | Oct 31, 2025 | 4.54M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 3.58M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $3.58M | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | $2.74M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $5.00M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $3.84M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $2.80M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $6.25M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $3.31M | Jan 28, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $2.45M | Feb 26, 2026 |
| FY2025 | Oct 31, 2025 | 2.45M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 2.24M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $2.24M | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | $2.10M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $2.24M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $2.98M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $3.19M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $2.80M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $2.57M | Jan 28, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $10.68M | Feb 26, 2026 |
| FY2025 | Oct 31, 2025 | 10.68M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 8.35M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $8.35M | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | $8.20M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $7.95M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $7.95M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $6.74M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $7.37M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $6.78M | Jan 28, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $7.21M | Feb 26, 2026 |
| FY2025 | Oct 31, 2025 | 7.21M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 2.45M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $2.45M | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | $2.39M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $6.73M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $3.27M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $4.43M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $6.39M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $2.43M | Jan 28, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.17M | Feb 26, 2026 |
| FY2025 | Oct 31, 2025 | 1.17M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 502,525 | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $502.5K | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | $2.02M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $466.5K | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $850.9K | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $835.1K | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $2.26M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $565.3K | Jan 28, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 64.49M | Jan 29, 2026 |
| FY2025 | Oct 31, 2025 | $64.49M | Feb 26, 2026 |
| FY2025 | Oct 31, 2024 | $57.54M | Feb 26, 2026 |
| FY2025 | Oct 31, 2024 | 57.54M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $51.84M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $46.93M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $45.47M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $38.04M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $34.51M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $28.74M | Jan 28, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $6.38M | Feb 26, 2026 |
| FY2025 | Oct 31, 2025 | 6.38M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 4.42M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $4.42M | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | $3.41M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $3.54M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $4.42M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $3.64M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $3.88M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $4.35M | Jan 28, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $58.12M | Feb 26, 2026 |
| FY2025 | Oct 31, 2025 | 58.12M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | 53.13M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $53.13M | Feb 26, 2026 |
| FY2025 | Oct 31, 2023 | 48.43M | Jan 29, 2026 |
| FY2025 | Oct 31, 2023 | $48.43M | Feb 26, 2026 |
| FY2024 | Oct 31, 2022 | $43.38M | Jan 29, 2025 |
| FY2023 | Oct 31, 2021 | $41.05M | Jan 29, 2024 |
| FY2022 | Oct 31, 2020 | $34.40M | Jan 30, 2023 |
| FY2021 | Oct 31, 2019 | $30.63M | Feb 14, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 3.64M | Jan 29, 2026 |
| FY2025 | Oct 31, 2025 | $3.64M | Feb 26, 2026 |
| FY2025 | Oct 31, 2024 | 3.64M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $3.64M | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | $3.38M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $3.38M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $3.38M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $3.38M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $3.38M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $3.38M | Jan 28, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($3.28M) | Feb 26, 2026 |
| FY2025 | Oct 31, 2025 | (3.28M) | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | (7.41M) | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | ($7.41M) | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | ($11.05M) | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | ($14.18M) | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | ($18.48M) | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | ($23.43M) | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | ($26.77M) | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | ($31.99M) | Jan 28, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 28.68M | Jan 29, 2026 |
| FY2025 | Oct 31, 2025 | $28.68M | Feb 26, 2026 |
| FY2025 | Oct 31, 2024 | 22.48M | Jan 29, 2026 |
| FY2025 | Oct 31, 2024 | $22.48M | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | $24.45M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $22.93M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $17.75M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | $15.13M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $11.72M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | $7.51M | Jan 28, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Oct 31, 2020 | $573.1K | Jan 28, 2021 |
| FY2019 | Oct 31, 2019 | $1.06M | Jan 28, 2020 |
| FY2018 | Oct 31, 2018 | $1.52M | Feb 7, 2019 |
| FY2017 | Oct 31, 2017 | $7.28M | Jan 30, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Oct 31, 2024 | 0 | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | 0 | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | 0 | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | 0 | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | 0 | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | 0 | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | 0 | Jan 28, 2020 |
| FY2018 | Oct 31, 2017 | 0 | Feb 7, 2019 |
| FY2017 | Oct 31, 2016 | 0 | Jan 30, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Oct 31, 2024 | 0 | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | 0 | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | 0 | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | 0 | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | 0 | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | 0 | Jan 28, 2021 |
| FY2018 | Oct 31, 2018 | 0 | Feb 7, 2019 |
| FY2018 | Oct 31, 2017 | 0 | Feb 7, 2019 |
| FY2017 | Oct 31, 2016 | 0 | Jan 30, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 11.27M | Feb 26, 2026 |
| FY2025 | Oct 31, 2024 | 11.20M | Feb 26, 2026 |
| FY2024 | Oct 31, 2023 | 11.12M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | 10.92M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | 10.86M | Jan 30, 2023 |
| FY2021 | Oct 31, 2020 | 10.75M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | 10.72M | Jan 28, 2021 |
| FY2019 | Oct 31, 2018 | 10.64M | Jan 28, 2020 |
| FY2018 | Oct 31, 2017 | 9.14M | Feb 7, 2019 |
| FY2017 | Oct 31, 2016 | 9.09M | Jan 30, 2018 |